Company Description
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data.
The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease.
BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
| Country | United States |
| IPO Date | Feb 13, 2023 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Vininder Singh |
Contact Details
Address: 325 Ellington Blvd. Gaithersburg, Maryland United States | |
| Website | https://www.bullfrogai.com |
Stock Details
| Ticker Symbol | BFRG |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001829247 |
| CUSIP Number | |
| ISIN Number | US12021E1091 |
| Employer ID | 84-4786155 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vininder Singh | Founder, Chairman & Chief Executive Officer |
| Dane R. Saglio | Chief Financial Officer |
| J. T. Koffenberger | Chief Information Officer |
| Dr. Cetin Savkli Ph.D. | Chief AI Advisor & Member of Advisory Board |
| Dr. David P. Recker FACP, FACR, M.D. | Chief Medical Officer |
| Hon. Thomas W. Chittenden X, DPHIL, Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | SCHEDULE 13G | Filing |
| Jan 06, 2025 | 4 | Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 3 | Filing |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 25, 2024 | S-1/A | [Amend] Filing |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | S-1 | Filing |
| Oct 21, 2024 | 8-K | Current Report |